Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2022 08:30 ET | Source: Akari Therapeutics Plc

FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies

NEW YORK and LONDON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
January 04, 2022 07:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
December 30, 2021 11:03 ET | Source: Akari Therapeutics Plc

Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering

NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat...
December 03, 2021 07:45 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress

Sites opened in Phase III study of nomacopan in bullous pemphigoid (BP)Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)...
December 01, 2021 08:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders

NEW YORK and LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
October 26, 2021 08:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit

NEW YORK and LONDON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
October 25, 2021 08:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program

Nomacopan eyedrops reduced inflammation more than both standard treatments cyclosporin and the steroid dexamethasone in a model of allergic eye diseaseBuilding on early clinical data in atopic...
September 22, 2021 09:00 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference

NEW YORK and LONDON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...
September 22, 2021 08:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress

Currently opening sites for Phase III study of nomacopan in bullous pemphigoid (BP).Phase III study of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic...
September 10, 2021 08:30 ET | Source: Akari Therapeutics Plc

Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium

NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right